Drug-induced Pneumonitis Following the Administration of TAS-102

Abstract

A 59-year-old woman, diagnosed with advanced rectal cancer, presented with a low-grade fever and dyspnea on exertion after the 2nd cycle of TAS-102. TAS-102 has promising efficacy in patients with metastatic colorectal cancer. A CT scan revealed mosaic patterns with bilateral ground-glass opacities. The drug lymphocyte stimulation test for TAS-102 was strongly positive and serum β-D glucan level was elevated. The clinical course was compatible with TAS-102-induced pneumonitis combined with pneumocystis pneumonia (PCP). We herein report a rare case of drug-induced pneumonitis in a patient receiving TAS-102 in combination with PCP.

Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report

“… 9 ) Therefore, in the present case, we believe that everolimus caused noninfectious pneumonitis, which led to the elevated serum CEA concentration. Although few reports have described an elevated serum CEA concentration caused by drug-induced lung injury, 10 , 11 ) our case suggests that drug-induced pneumonitis elevates the serum CEA concentration by the same mechanism as in previously reported benign lung diseases, such as interstitial pneumonia. The serum CEA concentration is rarely measured during the follow-up period of RCC.…”

Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report

“…5 Furthermore, three cases of TAS-102-induced interstitial pneumonia were reported in Japan. [6][7][8] The two main mechanisms involved in the pathogenesis of drug-induced lung injury are as follows: first, direct cytotoxic pulmonary injury to the alveolar epithelial or vascular endothelial cells and activation of immune system. The cytotoxic mechanism is known to be related to the dosage and duration of administration and is associated with the development of diffuse alveolar damage (DAD).…”